FTC Seeks Public Comment on Policy Statement Addressing AI Accuracy [marketing-compliance]
The FTC announced on July 1, 2026 that it is seeking public comment on a proposed policy statement on AI accuracy, including concerns that AI companies may be manipulating outputs (ftc.gov). The press release is thin on specifics, but the direction matters for any clinic using AI chatbots for patient intake, AI-generated ad copy, or AI-written claims about GLP-1s, peptides, or hormone therapy: the FTC has already shown it will treat inaccurate AI output as a deception issue chargeable to the business deploying it, not just the AI vendor. A policy statement is not a rule, but it signals where enforcement attention goes next, and marketing-heavy telehealth is a soft target. If your funnel includes an AI chatbot answering treatment questions or generating outreach, inventory those touchpoints now and check who reviews the output before it reaches a patient. Read the full proposed statement when it posts to the docket, and ask counsel whether filing a comment makes sense for your operation before the deadline closes.
Source: ftc.gov (2026-07-01)

Bulk Manufacturer of Controlled Substances Application: Veranova, L.P. [telehealth-dea]
DEA published a notice on June 30, 2026 that Veranova, L.P. has applied for registration as a bulk manufacturer of controlled substances (federalregister.gov). This is an application, not a grant: registration only happens after DEA review, and the notice itself changes nothing about who can make what today. The specific drug classes are listed in the notice's supplementary information, and that list is the part worth reading, since new bulk manufacturing capacity can eventually affect API sourcing and pricing for anything scheduled that your formulary touches. These notices also open a window for existing registrants to comment or object, typically 30 days from publication. If your suppliers touch any of the listed classes, pull the notice, check the substances against your sourcing, and flag it to whoever manages your API contracts.
Source: federalregister.gov (2026-06-30)

FTC Requires Amazon to Pay $2.25 Million to Resolve Charges It Knowingly Violated the Fair Credit Reporting Act [marketing-compliance]
The FTC announced June 30, 2026 that Amazon will pay $2.25 million in civil penalties for allegedly refusing to give identity theft victims records of fraudulent transactions made with their stolen data, a Fair Credit Reporting Act violation (ftc.gov). The relevant hook for clinics: FCRA Section 609(e) obligates any business, not just credit bureaus, to hand over transaction records when an identity theft victim asks, and telehealth and cash-pay clinics sit on exactly the kind of card-on-file and patient-intake data that fraudsters exploit. If a stolen identity is used to book a consult or buy a membership at your clinic, you owe that victim the records, and "we don't do that" is now a penalty-priced answer. The FTC is signaling it will enforce this against companies of any size, and the "knowingly violated" framing means a documented refusal process is worse than no process. Check whether your front desk and billing team have a written procedure for identity theft record requests, and have counsel confirm it meets the 609(e) requirements before someone tests it.
Source: ftc.gov (2026-06-30)

Why Most Healthcare Founders Scale Too Early [operator-intel]
DJ Holt Law published a piece on July 1, 2026 arguing that healthcare founders expand to new locations or digital service lines based on top-line revenue while their compliance infrastructure stays built for a single clinic (djholtlaw.com). The failure mode is familiar in this space: a peptide or HRT clinic doing well in one state bolts on telehealth or a second site, and suddenly its corporate practice of medicine structure, supervision agreements, and pharmacy relationships are wrong for the new jurisdiction. Revenue growth masks the problem until a board complaint, payer audit, or state AG inquiry surfaces it, and by then the fix is expensive and retroactive. The piece's core point holds: governance has to be rebuilt for the footprint you are scaling into, not the one you started with. Before signing the next lease or launching in a new state, have counsel map your MSO structure, prescriber licensure, and compounding pharmacy arrangements against each target state's rules, and treat that review as a gating item, not a cleanup task.
Source: djholtlaw.com (2026-07-01)

Common CPOM Violations in California Med Spas [operator-intel]
A July 1, 2026 post from DJ Holt Law flags rising California enforcement against corporate practice of medicine violations in med spas, with regulators reportedly auditing legacy MSO arrangements for non-physician control over clinical decisions (djholtlaw.com). This is a law firm's read on enforcement trends, not a specific enforcement action, but the pattern it describes is consistent with what California operators have been reporting. The exposure points are familiar: MSO fee structures that skim clinical revenue, non-physician owners setting treatment menus or hiring clinicians, and medical directors in name only. If you run a California clinic through an MSO, the structure that passed review in 2021 may not survive a 2026 audit. Have your healthcare counsel re-paper the MSO agreement and confirm the physician entity actually controls hiring, protocols, and clinical revenue, not just on paper.
Source: djholtlaw.com (2026-07-01)

Why Regulators Have Lost Control of the Peptide Market in the United States [glp1-enforcement]
DJ Holt Law published an argument on July 1, 2026 that federal regulators have effectively lost control of the US peptide market, pointing to the gap between FDA's stated position on compounds like BPC-157 and the open trade happening on forums, social media, and gray-market sites (djholtlaw.com). This is one attorney's read, not a policy signal, but the framing matters: when the enforcement gap gets this visible, it tends to invite a correction, and corrections usually land on the easiest targets first, meaning licensed clinics and pharmacies with addresses and DEA numbers, not anonymous research-chemical sites. An enforcement lull is not a safe harbor, and nothing in this piece changes what any clinic can legally source or dispense. If your protocols include peptides outside products that carry FDA approval or valid compounding channels, this is a good week to have counsel re-audit your sourcing, marketing claims, and prescriber documentation before the gap closes on someone.
Source: djholtlaw.com (2026-07-01)

CMS goes live with GLP-1 Bridge program for Part D beneficiaries [glp1-enforcement]
CMS launched its GLP-1 "bridge" model on July 7, 2026, extending Part D coverage of GLP-1s for weight loss to Medicare beneficiaries, per Fierce Healthcare (fiercehealthcare.com). For clinics with cash-pay weight-loss programs, this changes the math on your 65-plus panel: patients who were paying out of pocket for branded GLP-1s may now have a covered pathway, and some will ask about it this week. Expect plan-by-plan variation in formulary placement, prior auth requirements, and which products qualify, since a model launch is not the same as uniform coverage. This also tightens the squeeze on compounded GLP-1 positioning for Medicare-age patients, where a covered branded option undercuts the usual access argument. Pull your Medicare-eligible patient list, check which Part D plans in your market are participating, and have your billing team confirm prior auth criteria before you promise anyone coverage.
Source: fiercehealthcare.com (2026-07-07)

WuXi AppTec seeks injunction over China military list [compounding-bulks]
WuXi AppTec filed for a preliminary injunction on June 29 to suspend its designation on the Pentagon's list of companies with alleged Chinese military ties, per Endpoints News on July 1, 2026 (endpoints.news). Why you care: WuXi sits upstream of a large share of the API and peptide raw material supply that feeds US compounding pharmacies and outsourcing facilities. If the listing stands, expect procurement friction, longer lead times, and pricing pressure as pharmacies shift sourcing away from listed entities, and if the injunction succeeds, expect the uncertainty to drag on instead. Nothing here changes which substances a clinic may compound, this is a supply chain and counterparty risk story, not a regulatory one. Ask your compounding pharmacy partners, whether 503A or 503B, where their bulk API originates and whether they have qualified a second source, and get that answer in writing before your next contract renewal.
Source: endpoints.news (2026-07-01)

List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period [compounding-bulks]
FDA extended the comment period on its May 1, 2026 proposal to keep semaglutide, tirzepatide, and liraglutide off the 503B Bulks List, the roster of substances outsourcing facilities can use in compounding (June 26, 2026, federalregister.gov). The extension came in response to a request for more time, which usually signals meaningful pushback in the docket, and it gives the industry a longer window to argue clinical need. This is 503B only: it says nothing about 503A pharmacy compounding, which runs on a separate list and separate nomination process. If your clinic sources GLP-1s from an outsourcing facility, this docket is where the future of that supply gets argued. Pull the notice, note the new deadline, and if you have documented clinical-need evidence, get it into the record before comments close, ideally coordinated through your trade association or counsel.
Source: federalregister.gov (2026-06-26)

Read the primary source and note the dates: federalregister.gov

Read the primary source and note the dates: ftc.gov

Read the primary source and note the dates: federalregister.gov

Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act (2026-07-01, federalregister.gov)

Bulk Manufacturer of Controlled Substances Application: Veranova, L.P. (2026-06-30, federalregister.gov)

List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period (2026-06-26, federalregister.gov)

FTC Seeks Public Comment on Policy Statement Addressing AI Accuracy (ftc.gov)

FTC Requires Amazon to Pay $2.25 Million to Resolve Charges It Knowingly Violated the Fair Credit Reporting Act (ftc.gov)

Why Most Healthcare Founders Scale Too Early (djholtlaw.com)

Common CPOM Violations in California Med Spas (djholtlaw.com)

Why Regulators Have Lost Control of the Peptide Market in the United States (djholtlaw.com)

CMS goes live with GLP-1 Bridge program for Part D beneficiaries (fiercehealthcare.com)

WuXi AppTec seeks injunction over China military list (endpoints.news)

None today.